Study: U.S. experiences rapid growth in specialty drug spending
Specialty drugs more than doubled as a share of retail fills for the overall U.S. population between 2010 and 2017, according to a study using various sources and published in Health Affairs, growing from 1% to 2.3%.
Despite representing a small percentage of overall prescriptions, spending on these drugs accounted for approximately half of the country’s total spending on retail, mail-order and provider-administered drugs in 2018; however, the study noted that the cost of these drugs are difficult to track due to the use of manufacturer rebates.
Net spending was divided at 31.5% for all retail and mail-order drugs for Medicare Part D, 37.8% for Medicaid and 43.6% of private drug spending.
Related News Articles
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program. “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…